Drug Profile
ADXS 31164
Alternative Names: ADXS-cHER2; ADXS-HER2; ADXS-HER2 construct vaccine; ADXS31-164; Lovaxin B; OST-HER2; OST31-164Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer OS Therapies
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Osteosarcoma
- Phase II Breast cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 26 Sep 2023 OS Therapies completes enrolment in its phase II trial for Osteosarcoma in the USA (Parenteral)
- 21 Sep 2023 OS Therapies completes a phase II trial in Osteosarcoma (Recurrent) in USA (Parenteral) (NCT04974008)
- 24 Jan 2023 Phase-II clinical trials in Breast cancer in USA (Parenteral) (OS Therapies pipeline; January 2023)